XML 59 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Feb. 28, 2017
USD ($)
Nov. 30, 2015
item
Feb. 28, 2015
Jan. 31, 2015
item
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
License agreements                          
Long term investment             $ 121,381       $ 121,381   $ 134,356 [1]
Research and development expense             292,527   $ 269,557   893,719 $ 879,263  
Unrealized gain (loss) on long term investments             (9,949)   23,045   (21,911) (2,343)  
Cash and cash equivalents             1,112,179       $ 1,112,179   899,509 [1]
Agenus                          
License agreements                          
Number of program targets | item       3   4              
Royalty payments on future global net sales (as a percent)                     15.00%    
Period of notice for termination of license agreement     12 months                    
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                          
License agreements                          
Royalty payments on future global net sales (as a percent)                     6.00%    
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                          
License agreements                          
Royalty payments on future global net sales (as a percent)                     12.00%    
Additional milestone payments under the license agreement     $ 510,000                    
Agenus | Development Milestones                          
License agreements                          
Upfront payment under license agreement                         20,000
Additional milestone payments under the license agreement             5,000 $ 5,000   $ 5,000 $ 5,000    
Agenus                          
License agreements                          
Long term investment             38,000       38,000   57,900
Research and development expense             $ 1,000   29,700   $ 3,800 48,600  
Shares owned following stock purchase (as a percent)     11.00%   9.00%                
Ownership percentage (as a percent)             16.00%       16.00%    
Unrealized gain (loss) on long term investments             $ (2,300)   10,200   $ (19,900) 6,800  
Total revenues               15,900   17,500      
Net income (loss)               25,200   79,500      
Cash and cash equivalents               43,200   $ 43,200      
Operating expenses               $ 32,500          
Agenus | Accrued and other liabilities                          
License agreements                          
Accrued and other liabilities             $ 2,200       $ 2,200   $ 3,200
Agenus | Stock purchase agreement                          
License agreements                          
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                      
Purchase price of common stock   $ 60,000                      
Per share price | $ / shares $ 4.40 $ 6.00                      
Discount for lack of marketability $ 4,500                        
Fair value of shares on the issuance date 39,500                        
Total consideration paid $ 60,000                        
Long term investment                 $ 39,500     39,500  
Research and development expense                       $ 20,500  
[1] The condensed consolidated balance sheet at December 31, 2017 has been derived from the audited financial statements at that date.